Arcellx Earnings Call Transcripts
Fiscal Year 2025
-
Anito-cel shows high efficacy, durable responses, and a favorable safety profile, setting it apart from other CAR T and bispecific therapies. With strong clinical trial results, imminent BLA submission, and robust commercial readiness, it is positioned for broad adoption and potential market expansion.
-
Anito-cel continues to show strong efficacy and a differentiated safety profile in late-line multiple myeloma, with no delayed neurotoxicity observed and high MRD negativity rates. Regulatory and commercial plans remain on track for a 2026 launch, with expansion into earlier lines and additional pipeline progress ongoing.
-
Anito-cel is positioned for a broad US launch in 2026, targeting a $12B+ myeloma CAR T market with strong clinical efficacy, a differentiated safety profile, and operational advantages through Kite. Physician and patient feedback highlight its potential for rapid adoption and expanded use, including in frail populations.
-
iMMagine-1 trial data for anito-cel show strong efficacy and a differentiated safety profile, with no delayed neurotoxicity observed and manufacturing readiness for launch. Regulatory filings are on track for a mid-to-late 2026 launch, with priority review expected.
-
Anito-cel is positioned as a best-in-class BCMA therapy for multiple myeloma, showing strong efficacy and a differentiated safety profile with no delayed neurotoxicities in over 155 patients. Manufacturing and access advantages, a robust pipeline, and a favorable partnership with Kite-Gilead support a 2026 launch and long-term growth.
Fiscal Year 2024
-
Anito-cel demonstrated high response rates, deep MRD negativity, and a favorable safety profile with minimal neurotoxicity in relapsed/refractory myeloma. Manufacturing is highly reliable, and broad access is supported by Kite's infrastructure. Physicians expect rapid adoption and increased outpatient use.